Published in Crit Rev Oncol Hematol on August 01, 1998
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood (2013) 2.38
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des (2008) 1.82
Asparagine synthetase chemotherapy. Annu Rev Biochem (2006) 1.82
Failure of amino acid homeostasis causes cell death following proteasome inhibition. Mol Cell (2012) 1.77
Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia. Blood (2015) 1.42
Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs (2006) 1.39
Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci (2000) 1.11
Acute pancreatitis in children and adolescents. World J Gastrointest Pathophysiol (2014) 1.06
Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J (2001) 1.02
The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med (2009) 1.02
Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal (2014) 1.01
Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res (2013) 0.99
Purification and characterization of a novel and robust L-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anti-cancerous properties. PLoS One (2014) 0.91
High-throughput asparaginase activity assay in serum of children with leukemia. Int J Clin Exp Med (2013) 0.90
Methanothermobacter thermautotrophicus tRNA Gln confines the amidotransferase GatCAB to asparaginyl-tRNA Asn formation. J Mol Biol (2008) 0.90
Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies. Br J Pharmacol (2013) 0.89
Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy. Proc Natl Acad Sci U S A (2014) 0.88
Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). J Pediatr Hematol Oncol (2011) 0.88
Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment. Mol Syndromol (2016) 0.88
Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J Control Release (2013) 0.87
Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia. Clin Med Insights Oncol (2014) 0.87
High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. JIMD Rep (2012) 0.86
Functional analysis of a novel DNA polymorphism of a tandem repeated sequence in the asparagine synthetase gene in acute lymphoblastic leukemia cells. Leuk Res (2008) 0.85
Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells. Mol Cancer Ther (2013) 0.84
Investigation of protective effect of L-carnitine on L-asparaginase-induced acute pancreatic injury in male Balb/c mice. Dig Dis Sci (2014) 0.82
Refolding and purification of recombinant L-asparaginase from inclusion bodies of E. coli into active tetrameric protein. Front Microbiol (2014) 0.81
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemother Pharmacol (2014) 0.81
Engineering of Helicobacter pylori L-asparaginase: characterization of two functionally distinct groups of mutants. PLoS One (2015) 0.80
Components of cancer metabolism and therapeutic interventions. Mitochondrion (2014) 0.80
Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther (2015) 0.79
Experimental Data in Support of a Direct Displacement Mechanism for Type I/II l-Asparaginases. J Biol Chem (2016) 0.79
Mitigation of acrylamide by l-asparaginase from Bacillus subtilis KDPS1 and analysis of degradation products by HPLC and HPTLC. Springerplus (2016) 0.78
Current applications and different approaches for microbial l-asparaginase production. Braz J Microbiol (2016) 0.78
Structural and kinetic characterization of guinea pig L-asparaginase type III. Biochemistry (2014) 0.78
An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo. Evid Based Complement Alternat Med (2013) 0.78
Arginine deprivation therapy for malignant melanoma. Clin Pharmacol (2012) 0.78
L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels. Drugs R D (2012) 0.78
Purification and Characterization of Glutaminase Free Asparaginase from Enterobacter cloacae: In-Vitro Evaluation of Cytotoxic Potential against Human Myeloid Leukemia HL-60 Cells. PLoS One (2016) 0.78
Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. Hematol Rep (2014) 0.77
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma (2015) 0.77
Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice. J Biol Chem (2013) 0.76
Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis). Int J Mol Med (2015) 0.76
Purification, Characterization and Comparison between Two New L-asparaginases from Bacillus PG03 and Bacillus PG04. Open Biochem J (2016) 0.75
Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity. PLoS One (2015) 0.75
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica (2016) 0.75
Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation. PLoS One (2013) 0.75
L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors. Mol Ther Oncolytics (2015) 0.75
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma (2015) 0.75
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. Haematologica (2017) 0.75
Off label use--label off use? Ann Oncol (2003) 1.75
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia (2001) 1.67
Critical limb ischaemia: initial treatment and predictors of amputation-free survival. Eur J Vasc Endovasc Surg (2011) 1.49
Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol (1994) 1.24
Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol (1997) 1.13
Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J (2007) 1.13
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia (2008) 1.12
Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol (2001) 1.02
Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol (1999) 1.01
Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol (2000) 1.00
Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Cancer (2000) 0.97
Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer (2006) 0.95
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs (2001) 0.92
Randomized clinical trials in children--ethical and methodological issues. Curr Pharm Des (2010) 0.91
Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. Ann Oncol (2004) 0.88
Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia (1998) 0.87
Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol (2003) 0.86
Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr (2005) 0.84
All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation. Ann Oncol (1999) 0.84
Simultaneous determination of all-trans-, 13-cis- and 9-cis-retinoic acid, their 4-oxo metabolites and all-trans-retinol in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl (1996) 0.83
Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia (2003) 0.83
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. Klin Padiatr (2002) 0.82
[Improved treatment results in children with AML: Results of study AML-BFM 93]. Klin Padiatr (2001) 0.82
Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer (2006) 0.81
Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. Br J Haematol (2000) 0.81
Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography. J Chromatogr A (1996) 0.81
Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs. Eur J Cancer (1998) 0.81
[Pharmacokinetic aspects of oral administration of etoposide]. Klin Padiatr (1998) 0.80
Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough. Pediatr Transplant (2008) 0.80
Chemically induced isomerization and differential uptake modulate retinoic acid disposition in HL-60 cells. FASEB J (1998) 0.80
Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Anticancer Drugs (1997) 0.80
Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis. J Chromatogr B Biomed Sci Appl (2001) 0.80
Development of hypertension in neuroblastoma during therapy: a case report. Med Pediatr Oncol (1993) 0.80
Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol (1999) 0.79
Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol (2001) 0.79
Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol (1996) 0.79
[HIT-GBM: multicenter study of treatment of children with malignant glioma]. Klin Padiatr (1996) 0.79
[Non-commercial clinical trials--who will be the legal sponsor? Sponsorship of investigator-initiated clinical trials according to the German Drug Law]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2006) 0.78
Short-term versus continuous infusion: no influence on ifosfamide side-chain metabolism. Eur J Cancer (1995) 0.78
Asparaginase decreases clotting factors in vitro: a possible pitfall? Int J Clin Lab Res (1995) 0.78
Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay. Cancer Chemother Pharmacol (2005) 0.77
Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. Int J Clin Pharmacol Ther (1998) 0.77
Population pharmacokinetic approach to compare oral and i.v. administration of etoposide. Anticancer Drugs (1999) 0.77
Phase II study of gemcitabine in children with relapsed leukemia. Pediatr Blood Cancer (2006) 0.77
Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis. Electrophoresis (1998) 0.77
Second temporal remission in a malignant glioma with trofosfamide and etoposide: a case report. Klin Padiatr (1996) 0.77
Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis. J Neurol Sci (1997) 0.76
Ethical approval for multicentre clinical trials in children. Contrasting systems in three European countries. Eur J Cancer (2002) 0.76
Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma (2002) 0.76
Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia--the need for a prospective multicentre study. Blood Coagul Fibrinolysis (1995) 0.76
[The control of hip dysplasia in Switzerland. A retrospect of the past 24 years]. Schweiz Arch Tierheilkd (1995) 0.76
Simulation tool for schedule-dependent etoposide exposure based on pharmacokinetic findings published in the literature. Anticancer Drugs (2001) 0.75
Loss of activity of Erwinia asparaginase on repeat applications. J Clin Oncol (1995) 0.75
Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group. Br J Cancer Suppl (1992) 0.75
Unphysiological effects contributing to asparaginase toxicity in vitro. Am J Physiol (1998) 0.75
Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haematol (1996) 0.75
[Antiinfectious prophylaxis in pediatric oncology. Work group "Quality Assurance" of Society for Pediatric Oncology and Hematology (GPOH)]. Klin Padiatr (1999) 0.75
[Drug development in paediatric oncology]. Klin Padiatr (2006) 0.75
Monitoring paracetamol metabolism after single and repeated administration in pediatric patients with neoplastic diseases. Int J Clin Pharmacol Ther (2007) 0.75
MOON-test - determination of motor performance in the pediatric oncology. Klin Padiatr (2013) 0.75
[Prognosis of children with acute myelocytic leukemia after first relapse]. Klin Padiatr (1998) 0.75
Therapy of childhood acute myelogenous leukemias. Ann Hematol (1996) 0.75
Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis. J Chromatogr B Biomed Sci Appl (1997) 0.75
[Solid phase-sample preparation of ifosfamide and chloroethyl metabolites in biological material. 1. Determination in plasma and urine]. Pharmazie (1992) 0.75
[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. Klin Padiatr (1996) 0.75
Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations. Eur J Pediatr (1997) 0.75
Pharmacokinetics of anticancer drugs in vitro. Adv Exp Med Biol (1999) 0.75
Pharmacokinetics of trofosfamide and its dechloroethylated metabolites. Cancer Chemother Pharmacol (1997) 0.75
Use of PEG-asparaginase in the treatment of patients with solid tumors. Cancer Chemother Pharmacol (2001) 0.75
[Effect of etamsylate on hemorrhagic diathesis of children with oncologic diseases. Retrospective matched-pair analysis of 64 patients in a study of 100 patients of the Münster University Pediatric Clinic]. Klin Padiatr (1991) 0.75
[Solid state sample preparation of ifosfamide and dechloroethyl- metabolites in biological material. 2. Consideration of the separation mechanism]. Pharmazie (1993) 0.75
Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica (1996) 0.75
Meeting report: pharmacology in pediatric oncology. Summary of the 10th international expert meeting of the Kind Philipp Foundation for leukemia research, June 10 - 13, 2001 at the Schloss Reisensburg, Günzburg an der donau. Klin Padiatr (2002) 0.75
Capillary electrophoretic drug monitoring of methotrexate and leucovorin and their metabolites. J Chromatogr B Biomed Sci Appl (1998) 0.75
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells. Leukemia (2001) 0.75
Determination of (E)-5-(2-bromovinyl)-2'-deoxyuridine in plasma and urine by capillary electrophoresis. J Chromatogr B Biomed Sci Appl (1999) 0.75